Endothelial Dysfunction in Men: The Hidden Vascular Damage That Precedes Heart Attack

Most men who have a heart attack had no warning. Or so they think. In reality, the vascular biology that produces a myocardial infarction unfolds over decades, and one of its earliest and most measurable expressions is endothelial dysfunction, a condition that can be present ten or twenty years before any plaque is visible on imaging. Understanding endothelial dysfunction means understanding why two men with the same cholesterol level can have dramatically different cardiovascular outcomes, and why some vascular damage is already accumulating in a man’s 30s while he still considers himself healthy.

What the Endothelium Actually Does

The endothelium is a single cell layer lining the interior of every blood vessel in the body. If laid out flat, the human endothelium would cover roughly the area of a tennis court. Despite being only one cell thick, it is one of the most metabolically active tissues in the body, functioning as a continuous sensor and regulator of vascular tone, inflammation, and hemostasis.

Its central product is nitric oxide, or NO, a signaling molecule synthesized by the enzyme endothelial nitric oxide synthase, known as eNOS. Nitric oxide diffuses into underlying smooth muscle cells and triggers relaxation, causing the vessel to dilate. This vasodilatory function is how the endothelium matches blood flow to the metabolic demands of tissue.

But nitric oxide does considerably more than vasodilate. It inhibits platelet aggregation, reducing the tendency for clots to form on vessel walls. It suppresses the expression of adhesion molecules that attract inflammatory cells into the vessel wall. It limits smooth muscle proliferation, which is a key driver of plaque progression. It buffers oxidative stress. In short, a healthy endothelium producing adequate nitric oxide is one of the body’s most potent cardiovascular protective mechanisms.

Endothelial dysfunction, in its simplest definition, is impaired nitric oxide bioavailability. Either the endothelium produces less NO, or the NO that is produced is rapidly scavenged by reactive oxygen species before it can act. The functional result is a vessel that constricts when it should dilate, promotes inflammation when it should suppress it, and facilitates clot formation when it should prevent it. This is the vascular state that precedes atherosclerotic plaques by years to decades.

Why Men Are More Vulnerable at Younger Ages

Men accumulate cardiovascular risk factors earlier than women, and those risk factors are precisely the ones that damage the endothelium most aggressively.

Smoking is the single most potent endothelial toxin known. Cigarette smoke delivers a concentrated mixture of oxidants and reactive nitrogen species directly into the pulmonary circulation, which then distributes them systemically. These compounds oxidize and inactivate NO, uncouple eNOS (causing it to produce superoxide instead of nitric oxide), and trigger endothelial cell apoptosis. Even low-level smoking reduces brachial artery flow-mediated dilation, the gold-standard non-invasive measure of endothelial function. Men are more likely to smoke and to start earlier than women, and smoking-related endothelial injury begins within years of initiation.

Visceral obesity, far more common in men than women for hormonal and anatomical reasons, promotes endothelial dysfunction through multiple pathways. Visceral adipocytes secrete adipokines, including resistin and interleukin-6, that impair eNOS activity. They also drive insulin resistance, which reduces the phosphorylation of eNOS at sites required for NO production. The resulting state is low-grade systemic endothelial inflammation before any cardiometabolic threshold has been crossed on a standard lab panel.

Dyslipidemia, particularly elevated oxidized LDL, causes endothelial injury through lipid peroxidation of membrane phospholipids and activation of NADPH oxidase, generating superoxide that rapidly scavenges NO. Men tend to develop atherogenic dyslipidemia (elevated triglycerides, low HDL, small dense LDL) earlier than women, reflecting the earlier insulin resistance trajectory.

Hypertension creates endothelial shear stress injury, particularly at arterial bifurcations, and the resulting turbulent flow activates inflammatory transcription factors within the endothelial cell. Men develop hypertension on average a decade earlier than women.

The consequence of this earlier accumulation of risk factors is a steeper and earlier trajectory of endothelial dysfunction in men, which translates into earlier plaque development and earlier clinical cardiovascular events.

Testosterone’s Dual Role in Endothelial Health

Testosterone has a complex and dose-dependent relationship with endothelial function that is frequently misunderstood, particularly in the context of the widespread use of testosterone supplementation and anabolic steroids.

At physiologic levels, testosterone appears to support endothelial function. The evidence shows that testosterone upregulates eNOS expression and activity in vascular endothelial cells, contributing to vasodilatory tone. Some studies of men with hypogonadism (clinically low testosterone) show impaired endothelial function that partially improves with physiologic testosterone replacement. This has led some cardiologists to consider severe hypogonadism as a contributor to endothelial risk in older men.

However, supraphysiologic testosterone, meaning levels well above the normal physiologic range, produces the opposite effect. Exogenous androgens at high doses, as used in anabolic steroid misuse, reduce HDL cholesterol, increase visceral fat through indirect metabolic effects, promote erythrocytosis (which increases blood viscosity), and paradoxically impair vasodilation. Anabolic steroid users demonstrate markedly reduced flow-mediated dilation in multiple studies, consistent with severe endothelial dysfunction. Some also develop premature coronary artery disease, cardiomyopathy, and sudden cardiac death.

The clinical implication is that testosterone therapy in properly diagnosed hypogonadal men with physiologic replacement goals is a different physiologic scenario than unsupervised high-dose androgen use, and the cardiovascular effects are correspondingly different. Men using supraphysiologic testosterone, whether for bodybuilding or perceived performance enhancement, are causing measurable endothelial harm.

Measuring Endothelial Function

Flow-mediated dilation, or FMD, of the brachial artery is the research gold standard for assessing endothelial function non-invasively. The technique involves occluding the brachial artery with a blood pressure cuff for five minutes, then releasing the cuff and measuring the reactive hyperemia-induced dilation of the artery with ultrasound. A healthy endothelium produces a burst of NO in response to the shear stress of the returning blood flow, causing the artery to dilate by 7 percent or more. FMD below 7 percent predicts future major adverse cardiovascular events in multiple prospective cohort studies.

Men have lower baseline FMD values than women of equivalent age, independent of other risk factors. This difference appears by the third decade of life and widens progressively, suggesting that male sex is independently associated with earlier endothelial deterioration.

In clinical practice, FMD is not widely available because it requires skilled ultrasonographers and standardized laboratory conditions. A more accessible alternative is reactive hyperemia peripheral arterial tonometry, performed with a device called EndoPAT. This technique measures fingertip pulse wave amplitude changes after arm occlusion, reflecting digital endothelial vasodilatory capacity. It is less technically demanding than FMD and has been validated against FMD in large studies. The reactive hyperemia index derived from EndoPAT is a reproducible marker of endothelial function and has been used in clinical trials as an endpoint.

For most clinical settings, endothelial function is inferred indirectly from the constellation of risk factors rather than measured directly. A man with visceral obesity, insulin resistance, hypertension, dyslipidemia, and a smoking history has a high clinical probability of endothelial dysfunction even without formal FMD testing.

Erectile Dysfunction as a Vascular Early Warning

One of the most clinically accessible windows into a man’s endothelial health is erectile dysfunction. This connection is not coincidental or superficial; it reflects shared vascular biology and has been confirmed in large prospective studies.

Penile erection depends on endothelium-derived NO production from the cavernous endothelium, triggering relaxation of smooth muscle in the corpora cavernosa and the massive increase in penile blood flow that underlies engorgement. Endothelial dysfunction in the penile vasculature impairs this NO-dependent relaxation and is the predominant cause of organic erectile dysfunction in men over 40.

The artery size hypothesis explains why ED often precedes coronary artery disease as a clinical event. The penile cavernous arteries are approximately 1 to 2 millimeters in diameter. Coronary arteries are 2 to 4 millimeters. The femoral and carotid arteries are considerably larger. Atherosclerotic plaques that are not yet large enough to restrict flow in a 3-millimeter coronary artery are already sufficient to impair flow in a 1.5-millimeter penile artery. ED therefore functions as an early detection signal for systemic atherosclerosis that is already present but not yet symptomatic in the larger-caliber coronary vessels.

Thompson and colleagues demonstrated that men with erectile dysfunction had significantly higher rates of myocardial infarction and stroke over a ten-year follow-up, with an approximately two- to threefold increase in cardiovascular event risk compared with age-matched men without ED. 4 / Promising This finding has since been replicated in multiple large cohort studies and is now incorporated into cardiovascular risk assessment frameworks in several European guidelines.

The clinical implication is straightforward: a man presenting with erectile dysfunction should be evaluated not just for sexual health but for cardiovascular risk. ED in a 45-year-old man with metabolic risk factors is a vascular presentation, not merely a urologic one.

Exercise as the Most Potent Endothelial Intervention

Among all lifestyle interventions studied for endothelial function, aerobic exercise has the most substantial and reproducible evidence base. The mechanism is well established: repeated bouts of increased blood flow during exercise create pulsatile shear stress on the endothelium, which upregulates eNOS expression and activity through mechanosensitive signaling pathways. Over weeks to months of regular exercise, this translates into a durable increase in NO bioavailability and measurable improvement in FMD.

Hambrecht and colleagues demonstrated in a landmark study that four weeks of supervised aerobic exercise training produced significant improvements in brachial artery FMD in patients with established coronary artery disease, comparable to the endothelial benefits seen with statin therapy. 4 / Promising Importantly, the exercise group also showed increased eNOS expression in vessel segments and reduced endothelial superoxide production, confirming a direct mechanistic effect on the vascular wall.

For healthy men, the threshold for detectable endothelial benefit is relatively low. The evidence shows that even moderate-intensity aerobic activity, at 150 minutes per week or more, produces measurable FMD improvement within four to eight weeks. High-intensity interval training appears to produce faster and potentially larger FMD gains than moderate-intensity continuous exercise in some populations, though both modalities outperform sedentary behavior.

Resistance training alone has a less consistent effect on endothelial function and may acutely impair FMD immediately post-exercise, although the chronic effects in men who combine resistance and aerobic training appear neutral to mildly favorable. For men whose primary goal is endothelial health, aerobic exercise should form the foundation of any exercise prescription.

Diet and Endothelial Injury

Dietary patterns exert substantial influence on endothelial function through multiple mechanisms. The Mediterranean diet, characterized by high olive oil, vegetables, legumes, nuts, fish, and moderate wine consumption, improves endothelial function in multiple randomized and cohort studies. The benefit appears to stem from the combined anti-inflammatory and antioxidant effects of polyphenols, omega-3 fatty acids, and monounsaturated fats, rather than any single nutrient.

Ultraprocessed foods are associated with endothelial harm through several pathways. Trans fatty acids, once ubiquitous in partially hydrogenated oils, impair eNOS activity and increase endothelial oxidative stress. Although trans fat content has been largely eliminated from the food supply in many countries, residual sources persist. High-fructose corn syrup drives de novo lipogenesis, raises triglycerides, and promotes insulin resistance, all of which converge on endothelial dysfunction. Advanced glycation end products (AGEs), produced when foods are cooked at high heat, trigger receptor-mediated endothelial oxidative stress.

Dietary sodium restriction reduces endothelial dysfunction in hypertensive individuals partly through blood pressure reduction and partly through direct effects on endothelial oxidative stress. High sodium intake activates the RAAS and increases sympathetic tone, both of which contribute to endothelial impairment independent of the blood pressure effect.

Inflammation, hsCRP, and Statins

Endothelial dysfunction is both a cause and a consequence of vascular inflammation. Dysfunctional endothelial cells upregulate adhesion molecules (VCAM-1, ICAM-1) and secrete cytokines that attract monocytes into the vessel wall, initiating the foam cell formation that characterizes early atherosclerotic lesions. The inflammatory marker hsCRP (high-sensitivity C-reactive protein), while a nonspecific marker of systemic inflammation, reflects the inflammatory activity of vessels and adipose tissue.

An hsCRP above 3 mg/L in the absence of acute infection or other inflammatory conditions is associated with higher cardiovascular event risk, and the evidence shows it reflects underlying endothelial inflammatory activity. The JUPITER trial demonstrated that rosuvastatin in individuals with elevated hsCRP and average LDL cholesterol reduced cardiovascular events substantially, supporting the concept that the inflammatory pathway is an independent therapeutic target.

Statins improve endothelial function through mechanisms that go beyond LDL lowering. They increase eNOS activity through upregulation of eNOS mRNA stability and reduction of eNOS inhibitors. They reduce endothelial oxidative stress and suppress the mevalonate pathway products (geranylgeranyl pyrophosphate and farnesyl pyrophosphate) that promote Rho-kinase-mediated eNOS inhibition. These pleiotropic endothelial effects are measurable within days to weeks, well before any significant LDL lowering could explain vascular benefit.

For men with elevated hsCRP and an intermediate cardiovascular risk score, some cardiologists now consider statin initiation as a strategy targeting both lipid and endothelial inflammatory risk.

L-Arginine and Supplement Claims

L-arginine, the amino acid substrate for eNOS and therefore for NO synthesis, has attracted considerable interest as a nutritional supplement for endothelial health. The rationale is straightforward: if more substrate is available, more NO should be produced.

Clinical evidence, however, has been disappointing. Multiple trials of L-arginine supplementation in both healthy individuals and patients with cardiovascular disease have shown marginal or no benefit on endothelial function or clinical outcomes. The reason is likely that endothelial dysfunction is not, in most patients, caused by L-arginine deficiency. The limiting factors are eNOS uncoupling, oxidative scavenging of NO, and reduced eNOS expression, none of which are addressed by adding more substrate.

A randomized trial in patients after myocardial infarction (VINTAGE MI) found no benefit from L-arginine supplementation and a nonsignificant trend toward harm. L-arginine supplements are not a substitute for addressing the root causes of endothelial dysfunction through risk factor management.

Putting It Together for Clinical Practice

Endothelial dysfunction is not a diagnosis that typically appears on a cardiology report or an insurance form. It is a physiologic state, and its clinical relevance lies in its position at the beginning of the atherosclerotic cascade, upstream of plaques, stenoses, and events.

For men with known risk factors, particularly the combination of smoking history, metabolic syndrome, early hypertension, or erectile dysfunction, the implication is that vascular biology is already operating in a pathologic mode, even if imaging and standard labs appear reassuring. The opportunity in this window before clinical events is substantial: exercise, dietary improvement, smoking cessation, and appropriate pharmacotherapy (statins, antihypertensives, RAAS blockade where indicated) can each contribute to endothelial recovery and reduced event risk.

The endothelium is a tissue. It responds to insults, and it responds to repair. For men willing to engage with the biology of their vascular risk, endothelial dysfunction represents not just a warning but a reversible process, and the earlier interventions begin, the more completely that reversal can occur.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.